Risk of upper gastrointestinal adverse events in Malaysian rheumatic patients on long-term non-steroidal antiinflammatory drugs
Journal Title: International Journal of Clinical Rheumatology - Year 2018, Vol 13, Issue 3
Abstract
Background: Non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (GI) adverse events are well-described in the Western population but data is lacking in Asian patients. This study aims to describe the incidence and predictive factors for NSAID-induced upper GI complications in a cohort of multi-ethnic patients in Malaysia. Methods and Findings: A retrospective cohort study was conducted in adult patients with rheumatoid arthritis (RA) and/or osteoarthritis (OA) from 2010-2013 in four main rheumatology centres in Malaysia with computerized clinical and pharmaceutical records. Clinical, pharmaceutical and demographic data over a 24-months follow-up period were analysed in subjects who were prescribed long-term NSAID therapy (defined as a minimum duration of four weeks). 634 patients were included in the final analysis with the following characteristics: mean age 53.4 ± 12.5 years, 89.9% female, diagnosis: RA 59.5%, OA 10.2% and RA/OA combination 30.3%. 371 (58.5%) patients received non-selective NSAIDs and 263 (41.5%) patients received COX-2 inhibitors. There were a total of 84 GI adverse events during the period of study, giving an incidence rate of 66.2 per 1000 person-years and a risk of 13.2%. The majority of upper GI adverse events was dyspepsia (92.9%), and only 7.1% with peptic ulcer disease/ upper GI bleeding. Multivariate analysis showed that the only independent predictive factor of upper GI adverse event in this cohort was a history of upper GI disease (O.R. 2.073, 95% C.I. 1.029 – 4.176). COX-2 inhibitor showed a trend towards, but not independently predictive of, GI protection in this analysis (OR 0.643; 95% C.I. 0.397 – 1.043). Conclusion: Malaysian rheumatic patients on long-term NSAID therapy, managed at referral centres, have a 13.2% risk of upper GI adverse events, with dyspepsia being the commonest complication. Patients with a history of upper GI disease were twice as likely to develop further upper GI adverse events with the use of long-term NSAIDs.
Authors and Affiliations
Lydia Say Lee Pok, Fatiha Hana Shabaruddin, Maznah Dahlui, Sargunan Sockalingam, Mohd Shahrir Said, Azmillah Rosman, Ing-Soo Lau, Liza Mohd Isa, Heselynn Hussein, Chin Teck Ng, Sanjiv Mahadeva
Keywords
Related Articles
- EP ID EP604496
- DOI -
- Views 56
- Downloads 0
Risk of upper gastrointestinal adverse events in Malaysian rheumatic patients on long-term non-steroidal antiinflammatory drugs
Background: Non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (GI) adverse events are well-described in the Western population but data is lacking in Asian patients. This study aims to describe...
The role of miRNAs in autoimmune inflammatory diseases
MicroRNAs (miRNAs) are abundant short 21- 23 nucleotides-long non-coding RNAs that modulate virtually all eukaryotic gene expression processes during development and are crucial for sustaining optimal cell functions and...
Association of sarcoidosis and psoriasis: a difficult diagnosis
Sarcoidosis is a chronic multisystem disorder characterized by the formation of non caseating epithelioid cell granulomas affecting multiple organ systems. The role of the type 1 helper T (TH1) cells and type 17 helper T...
Improved clinical outcomes and physical activity in patients with rheumatoid arthritis treated with originator adalimumab in routine clinical practice
Background/Objective: We aimed at evaluating changes in habitual physical activity, disease activity and physical function following treatment with originator adalimumab (ADAORIG) in patients with Rheumatoid Arthritis (R...
Characteristics of fibromyalgia patients prescribed opioid medications: data from the Cleveland Clinic Fibromyalgia Registry
Objective: Determine the prevalence, socioeconomic, clinical characteristics of fibromyalgia (FM) patients and the factors associated with narcotic drug prescription. Methods: New patients with FM referred for rheumatol...